T 0562/04 (Factor VIII/von Willebrand factor complex/OCTAPHARMA) vom 14.02.2006
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2006:T056204.20060214
- Datum der Entscheidung
- 14. Februar 2006
- Aktenzeichen
- T 0562/04
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 93902233.1
- IPC-Klasse
- C07K 1/18
- Verfahrenssprache
- Englisch
- Verteilung
- An die Kammervorsitzenden verteilt (C)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Process for recovering a high-purity virus-inactivated factor VIII/von Willebrand factor complex by anion exchanger chromatography
- Name des Antragstellers
- Octapharma AG
- Name des Einsprechenden
- Baxter Healthcare S.A.
- Kammer
- 3.3.04
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 111(1) 1973European Patent Convention Art 113(1) 1973European Patent Convention Art 114(2) 1973European Patent Convention Art 123(2) 1973European Patent Convention Art 123(3) 1973European Patent Convention Art 54 1973European Patent Convention Art 56 1973European Patent Convention Art 83 1973European Patent Convention Art 84 1973European Patent Convention Art 87(1) 1973European Patent Convention Art 88 1973European Patent Convention Art 89 1973
- Schlagwörter
- Admissibility of late-filed documents - (yes)
Remittal - (no)
Main request - novelty (no)
Auxiliary request - added subject-matter, extension of scope of protection (no), clarity, novelty, sufficiency of disclosure, inventive step (yes) - Orientierungssatz
- -
- Zitierende Akten
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance with the order to maintain the patent in amended form on the basis of the following documents:
- claims 1 to 5 of auxiliary request I filed in the oral proceedings
- adapted description (pages 2 to 7 of the patent specification, including page 5a) filed in the oral proceedings.